No new SARS-CoV-2 variants detected in China since COVID policy change SARSCoV2 China Beijing Coronavirus Disease COVID TheLancet ChinaCDCWeekly
SARS-CoV-2 transmission was not persistently observed in China prior to December 2022 due to the implementation of the dynamic zero-COVID health strategy at a national level. However, overseas COVID-19 cases have been detected frequently in the country in the previous three years. The recent upsurge in COVID-19 case counts among Chinese individuals has raised concerns regarding the continual SARS-CoV-2 evolution in the country.
Respiratory specimens were obtained from local and overseas COVID-19 cases detected in Beijing in the previous three years and selected randomly for further analyses. SARS-CoV-2 ribonucleic acid was extracted from the specimens and subjected to polymerase chain reaction analysis and next-generation sequencing for generating SARS-CoV-2 genomes.
Information obtained from the participants was de-identified and analyzed by two professional individuals. A total of 1,686 cases of local SARS-CoV-2 infections were sequenced prior to November 14, 2022, of which the team randomly selected 350 local COVID-19 cases and subjected them to sequencing analysis between November 14 and December 20, 2022. In addition, 824 overseas cases were selected randomly and sequenced.
In total, 2,994 full-length SARS-CoV-2 genomic sequences were obtained, of which 2,881 high-quality sequences were analyzed further. Between November 14 and December 20, 413 specimens were sequenced, of which 63 and 350 belonged to overseas and local SARS-CoV-2 infection cases, respectively. All sequences were of known SARS-CoV-2 strains, with 114 sequences and 2,767 sequences of the SARS-CoV-2 Delta variant and SARS-CoV-2 Omicron variant, respectively, rather than of novel SARS-CoV-2 variants.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
A novel nomenclature system for pathogens like SARS-CoV-2A novel nomenclature system for pathogens like SARS-CoV-2 SARSCoV2 Coronavirus Disease COVID Antibiotic Chikungunya Encephalitis pathogen biorxivpreprint
Read more »
Researcher contextualizes a study on IgG4 anti-Spike levels after repeated SARS-CoV-2 mRNA vaccinationResearcher contextualizes a study on IgG4 anti-Spike levels after repeated SARS-CoV-2 mRNA vaccination ScienceMagazine ragoninstitute antibody antibodies spike mRNA vaccine SARSCoV2 COVID19 coronavirus covid
Read more »
Pregnancy outcomes after monoclonal antibodies infusion for COVID-19Pregnancy outcomes after monoclonal antibodies infusion for COVID-19 MDPIOpenAccess UninaIT univUda Unibo antibody antibodies COVID19 coronavirus covid pregnancy
Read more »
Study finds hospitalized obstetric patients with cardiovascular disease and COVID-19 are more symptomaticStudy finds hospitalized obstetric patients with cardiovascular disease and COVID-19 are more symptomatic PLOSONE usponline obstetrics cardiovasculardisease disease COVID19 covid coronavirus symptoms
Read more »
Novel COVID-19 protein component vaccine elicits durable immune response in rodentsNovel COVID-19 protein component vaccine elicits durable immune response in rodents Coronavirus Disease COVID ImmuneResponse Protein Vaccine biorxivpreprint RutgersU RWJMS
Read more »
Acute phase characteristics and long-term complications of pulmonary embolism in COVID-19 compared to non-COVID-19 cohort: a large single-centre study - BMC Pulmonary MedicineBackground To compare the severity of pulmonary embolism (PE) and the long-term complications between patients with and without COVID-19, and to investigate whether the tools for risk stratification of death are valid in this population. Methods We retrospectively included hospitalized patients with PE from 1 January 2016 to 31 December 2022. Comparisons for acute episode characteristics, risk stratification of the PE, outcomes, and long-term complications were made between COVID and non-COVID patients. Results We analyzed 116 (27.5%) COVID patients and 305 (72.4%) non-COVID patients. In patients with COVID-19, the traditional risk factors for PE were absent, and the incidence of deep vein thrombosis was lower. COVID patients showed significantly higher lymphocyte count, lactate dehydrogenase, lactic acid, and D-dimer levels. COVID patients had PE of smaller size (12.3% vs. 25.5% main pulmonary artery, 29.8% vs. 37.1% lobar, 44.7% vs. 29.5% segmental and 13.2% vs. 7.9% subsegmental, respectively; p | 0.001), less right ventricular dysfunction (7.7% vs. 17.7%; p = 0.007) and higher sPESI score (1.66 vs. 1.11; p | 0.001). The need for mechanical ventilation was significantly higher in COVID patients (8.6% vs. 1.3%; p | 0.001); However, the in-hospital death was less (5.2% vs. 10.8%; p = 0.074). The incidence of long-term complications was lower in COVID cohort (p | 0.001). PE severity assessed by high sPESI and intermediate and high-risk categories were independently associated with in-hospital mortality in COVID patients. Conclusion The risk of in-hospital mortality and the incidence of long-term complications were lower in COVID-19. The usual tools for risk stratification of PE are valid in COVID patients.
Read more »